Iktos and Curreio Ink Collaboration Agreement in New Drug Discovery

Our Portfolio company Iktos,  specialized in Artificial Intelligence for new drug design and Curreio, Inc. (Curreio), a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, announced a collaboration agreement in AI for new drug design. In this collaboration, Iktos’ de novo generative design technology in combination with Curreio’s state-of-the-art cryo-EM platform will be used to facilitate the rapid and cost-effective design of novel preclinical drug candidates for an undisclosed target.

In the context of the collaboration, Iktos’ generative AI technology will be combined with structure-based modelling, using insights produced thanks to Curreio’s cryo-EM platform to design structures maximizing protein-ligand interaction and with high probability of meeting the project’s Target Product Profile (TPP). Structural analysis technology using Cryo-EM is one of the best technologies in the three-dimensional structural analysis of biomolecules, and was awarded the Nobel Prize in Chemistry in 2017.

At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of drug discovery by combining our powerful algorithmic technology and our know-how derived from the experience of our many collaborations. We are therefore thrilled to enter into a research collaboration with Curreio, a specialist in structural analysis of biomolecules and to combine our technology platforms to accelerate structure-based drug discovery together

said Yann Gaston-Mathé, Co-founder and CEO of Iktos.

Access their full press release here